Letter to the Editor: Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy

doi:10.3748/wjg.v32.i21.116467

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 21

This Article

(7)

(6)

(0)

(7)

(106)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jun 7, 2026; 32(21): 116467
Published online Jun 7, 2026. doi: 10.3748/wjg.v32.i21.116467

Table 1 Key contributions of the study on IGF2BP3/FBXO32/cyclic guanosine monophosphate-protein kinase G axis in gastric cancer

Contribution category	Core content	Innovation & significance
Mechanistic elucidation	First reveals IGF2BP3 promotes GC via m⁶A-dependent regulation: Binds FBXO32 mRNA to upregulate its protein (no transcriptional change)	Fills IGF2BP3 downstream gap in GC; unique mechanism; identifies FBXO32 as key m⁶A effector
Axis identification	Identifies IGF2BP3/FBXO32/cGMP-PKG as GC driver; KT5823 (PKG inhibitor) reverses its oncogenic effects	Links cGMP-PKG to IGF2BP3/FBXO32 (novel in GC); validates druggable target
Translational relevance	High IGF2BP3 = poor prognosis (prognostic biomarker); axis targeting offers new therapy	Bridges preclinical-clinical translation; aids prognosis/treatment

cGMP: Cyclic guanosine monophosphate; PKG: Protein kinase G; m⁶A: N⁶-methyladenosine; GC: Gastric cancer.

Full Size Table

Citation: Xu S, Zhu Z, Shi PH, Xu YT, Zhang HM, Zheng Y, Chen YT, Lu GR, Zheng BJ. Letter to the Editor: Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy. World J Gastroenterol 2026; 32(21): 116467
URL: https://www.wjgnet.com/1007-9327/full/v32/i21/116467.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i21.116467

Xu S, Zhu Z, Shi PH, Xu YT, Zhang HM, Zheng Y, Chen YT, Lu GR, Zheng BJ. Letter to the Editor: Targeting the IGF2BP3/FBXO32/cGMP-PKG axis as a therapeutic modality for gastric cancer: A promising strategy. World J Gastroenterol 2026; 32(21): 116467 [DOI: 10.3748/wjg.v32.i21.116467]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.